1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Renal Failure - Pipeline Review, H1 2014

Renal Failure - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 43 pages

Renal Failure - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Renal Failure - Pipeline Review, H1 2014’, provides an overview of the Renal Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Renal Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Renal Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Renal Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Renal Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Renal Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Renal Failure - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Renal Failure Overview 6
Therapeutics Development 7
Pipeline Products for Renal Failure - Overview 7
Pipeline Products for Renal Failure - Comparative Analysis 8
Renal Failure - Therapeutics under Development by Companies 9
Renal Failure - Therapeutics under Investigation by Universities/Institutes 10
Renal Failure - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Renal Failure - Products under Development by Companies 13
Renal Failure - Products under Investigation by Universities/Institutes 14
Renal Failure - Companies Involved in Therapeutics Development 15
Pathfinder Cell Therapy, Inc. 15
3SBio Inc. 16
Virobay Inc. 17
Zyrnat Biotherapeutics SL 18
Liaoning Cheng Da Biotechnology Co., Ltd 19
Renal Failure - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Vaccine For Hemmorrhagic Fever With Renal Syndrome - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DAA-I - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Pathfinder Cells - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ZY-11 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
VBY-X - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
DJ5 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Ixac - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Renal Failure - Dormant Projects 38
Renal Failure - Discontinued Products 39
Renal Failure - Product Development Milestones 40
Featured News and Press Releases 40
Feb 05, 2013: La Jolla Pharma Receives Notice Of Allowance For Patent Covering Modified Pectin Compositions 40
Jul 24, 2012: BioCryst Pharma Announces Positive Results From Two Ulodesine Phase II Trials In Patients With Gout 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables

Number of Products under Development for Renal Failure, H1 2014 7
Number of Products under Development for Renal Failure - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Renal Failure - Pipeline by Pathfinder Cell Therapy, Inc., H1 2014 15
Renal Failure - Pipeline by 3SBio Inc., H1 2014 16
Renal Failure - Pipeline by Virobay Inc., H1 2014 17
Renal Failure - Pipeline by Zyrnat Biotherapeutics SL, H1 2014 18
Renal Failure - Pipeline by Liaoning Cheng Da Biotechnology Co., Ltd, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Renal Failure - Dormant Projects, H1 2014 38
Renal Failure - Discontinued Products, H1 2014 39

List of Figures

Number of Products under Development for Renal Failure, H1 2014 7
Number of Products under Development for Renal Failure - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.